The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data) was written by Mauri, Massimo Carlo;Franco, Gemma;Minutillo, Alessandro;Paletta, Silvia;Di Pace, Chiara;Reggiori, Alessandra;Baldelli, Sara;Cattaneo, Dario. And the article was included in Journal of Clinical Psychopharmacology in 2022.Application of 144598-75-4 This article mentions the following:
The aim of the study was a preliminary evaluation of the maintenance of clin. efficacy and tolerability of paliperidone palmitate in patients with schizophrenia during the transition phase from 1-monthly paliperidone palmitate formulation (PP1M) to PP3M, with the evaluation of plasma levels of the drug. A prospective observational study was conducted for 13 mo involving 22 outpatients, aged 18 to 66 years and clin. stabilized. Patients were affected by schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria. For each patient, clin. assessment, safety and tolerability, and drug plasma level determination were performed. Clin. efficacy was assessed by Brief Psychiatric Rating Scale, Pos. and Neg. Symptom Scale, and Hamilton Rating Scale for Depression. During the first 4 mo of the study, once-monthly paliperidone palmitate was administered, and then during the following 9 mo, the 3-monthly formulation was administered. The time course of the Brief Psychiatric Rating Scale total scores showed a statistically significant (P = 0.006) improvement from T0 to T8; Pos. and Neg. Symptom Scale scores showed a similar time course, with a statistically significant (P = 0.0016) reduction of the mean total score; Hamilton Rating Scale for Depression mean scores showed a statistically significant (P = 0.003) reduction with substantial maintenance of clin. stabilization of the patients. Only 1 patient dropped out after the first PP3M injection. Our preliminary data currently confirm the maintenance of clin. stability shifting from PP1M to PP3M. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application of 144598-75-4).
3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Application of 144598-75-4
Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem